Skip to main navigation Skip to search Skip to main content

Disrupting TP53 in mouse models of human cancers

Research output: Contribution to journalReview articlepeer-review

Abstract

Manipulation of the mouse genome allows emulation of the genetic defects that give rise to human cancers and evaluation of the cooperating nature of different mutations in the transformation of distinct cell types. Here we review the generation of mice with specific missense mutations in p53 (TP53) and disruption of the p53 pathway by deletion of p53 inhibitors. Missense mutations in the DNA binding domain result in viable mice with gain-of-function and dominant negative phenotypes. Loss of either of the p53 inhibitors mdm2 or mdm4 gives rise to a p53-dependent embryonic lethal phenotype. A cell can thus tolerate the absence of p53 function but not excess p53 function, a characteristic that is being exploited in the treatment of human cancers. Hum Mutat 21:321-326.

Original languageEnglish (US)
Pages (from-to)321-326
Number of pages6
JournalHuman mutation
Volume21
Issue number3
DOIs
StatePublished - 2003

Keywords

  • Animal model
  • Cancer
  • MDM2
  • MDM4
  • Mouse
  • Oncogene
  • P53
  • Suppressor
  • TP53
  • Tumor

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Fingerprint

Dive into the research topics of 'Disrupting TP53 in mouse models of human cancers'. Together they form a unique fingerprint.

Cite this